Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

Next Previous
Trial Profile

An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setanaxib (Primary)
  • Indications Bile duct diseases; Diabetic neuropathies; Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Calliditas Therapeutics

Most Recent Events

  • 08 Nov 2022 Results assessing the PK and drug-drug interactions of setanaxib tablets, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
  • 21 May 2021 Status changed from recruiting to completed.
  • 17 Jan 2021 Results published in the GenKyoTex Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top